Loading patent…
AssigneeQyuns Therapeutics Co., Ltd.
InventorsJiwan QIU, Yong KONG, Wei CHEN, Huaiyao QIAO, Zhihua QIU, Yiliang WU, Tao CHEN, Meijuan WU
Estimating the term…
The present invention relates to an anti-human interleukin 23 (hIL-23) monoclonal antibody and an application thereof. The anti-human interleukin 23 (hIL-23) monoclonal antibody comprises three heavy chain complementary determining regions (CDR-H1, CDR-H2 and CDR-H3) and three light chain complementary determining regions (CDR-L1, CDR-L2 and CDR-L3), wherein (a): the amino acid sequence of the CDR-H1 is as shown in SEQ ID NO: 1, (b): the amino acid sequence of the CDR-H2 is as shown in SEQ ID NO: 2, (c): the amino acid sequence of the CDR-H3 is as shown in SEQ ID NO: 3, (d): the amino acid sequence of the CDR-L1 is as shown in SEQ ID NO: 4, (e): the amino acid sequence of the CDR-L2 is as shown in SEQ ID NO: 5, and (f): the amino acid sequence of the CDR-L3 is as shown in SEQ ID NO: 6. Compared with existing anti-human interleukin 23 monoclonal antibodies (Guselkumab and Risankizumab), the hIL-23 binding affinity of the anti-human interleukin 23 (hIL-23) monoclonal antibody is equivalent, but the antagonistic activity at the cellular level is superior to Guselkumab, and equivalent to Risankizumab.
An isolated nucleic acid molecule encoding an anti-human interleukin 23 (IL-23) antibody comprising a heavy chain variable region comprising three heavy chain complementary determining regions (CDR-H1, CDR-H2 and CDR-H3) and a light chain variable region comprising three light chain complementary determining regions (CDR-L1, CDR-L2 and CDR-L3), wherein:
A host cell comprising a nucleic acid molecule encoding an anti-human IL-23 antibody comprising a heavy chain variable region comprising three heavy chain complementary determining regions (CDR-H1, CDR-H2 and CDR-H3) and a light chain variable region comprising three light chain complementary determining regions (CDR-L1, CDR-L2 and CDR-L3), wherein:
A method of producing an anti-human IL-23 antibody, the method comprising culturing a host cell comprising a nucleic acid molecule encoding an anti-human IL-23 antibody comprising a heavy chain variable region comprising three heavy chain complementary determining regions (CDR-H1, CDR-H2 and CDR-H3) and a light chain variable region comprising three light chain complementary determining regions (CDR-L1, CDR-L2 and CDR-L3), wherein:
Dependencies are inferred from the claim text.